Generated by All in One SEO v5.0.0.1, this is an llms.txt file, used by LLMs to index the site. # リベロセラ株式会社 無細胞膜タンパク質調製技術 および 非天然型アミノ酸導入技術 を用いた革新的な創薬を通じ医療に貢献します。 ## Sitemaps - [XML Sitemap](https://www.liberothera.com/sitemap.xml): Contains all public & indexable URLs for this website. ## 固定ページ - [Board Members](https://www.liberothera.com/english/company/board-members/) - [役員一覧](https://www.liberothera.com/corporate-info/officers/) - [Overview](https://www.liberothera.com/english/company/overview/) - [会社概要](https://www.liberothera.com/corporate-info/profile/) - [アライアンス](https://www.liberothera.com/alliance/) - [Locations](https://www.liberothera.com/english/locations/) - Head Office Nihonbashi Life Science Building 7, 8th Flo - [アクセス](https://www.liberothera.com/access/) - 本社 〒103-0012 東京都中央区日本橋堀留町1-9-10 日本橋ライフサイエンスビルディング７ 8階 T - [採用情報](https://www.liberothera.com/recruit/) - [Company History](https://www.liberothera.com/english/company/company-history/) - [会社沿革](https://www.liberothera.com/corporate-info/history/) - [非天然型アミノ酸導入技術](https://www.liberothera.com/technology/non-natural-amino-acids/) - [Partnering](https://www.liberothera.com/english/partnering/) - [Non-canonical Amino Acid Incorporation Technology](https://www.liberothera.com/english/technology/non-canonical-amino-acid/) - [Cell-free Membrane Protein Synthesis Technology](https://www.liberothera.com/english/technology/membrane-protein/) - [Business model](https://www.liberothera.com/english/business/business-model/) - [Business Overview](https://www.liberothera.com/english/business/business-overview/) - [膜タンパク質調製技術](https://www.liberothera.com/technology/membrane-protein/) - [ビジネスモデル](https://www.liberothera.com/business-content/business-model/) - [事業概要](https://www.liberothera.com/business-content/summary/) - [Contact Us](https://www.liberothera.com/english/contact/) - [mwform_formkey key="556"] - [お問い合わせ](https://www.liberothera.com/contact/) - [mwform_formkey key="166"] - [Privacy Policy](https://www.liberothera.com/english/privacypolicy/) - [Sitemap](https://www.liberothera.com/english/sitemap/) - Company CEO Message Overview Board Members Company Hist - [Technology](https://www.liberothera.com/english/technology/) - [Business](https://www.liberothera.com/english/business/) - [Company](https://www.liberothera.com/english/company/) - [HOME](https://www.liberothera.com/english/) - [プライバシーポリシー](https://www.liberothera.com/privacypolicy/) - [サイトマップ](https://www.liberothera.com/sitemap/) - [テクノロジー](https://www.liberothera.com/technology/) - [事業内容](https://www.liberothera.com/business-content/) - [企業情報](https://www.liberothera.com/corporate-info/) ## ニュース - [新代表取締役就任のお知らせ](https://www.liberothera.com/news/新代表取締役就任のお知らせ/) - [リベロセラ、追加出資ラウンドで総額7.2億円の資金調達に合意](https://www.liberothera.com/news/リベロセラ、追加出資ラウンドで総額7-2億円の資/) - [2024年開催の米国癌学会における抗CCR8抗体のデータ発表について](https://www.liberothera.com/news/2024年開催の米国癌学会における抗ccr8抗体のデータ発/) - [リベロセラは、国立がん研究センター等が実施するベンチャー支援プログラム「NCC Venture Incubation Program」の2022年度支援チームとして選定されました。](https://www.liberothera.com/news/0704-2022/) - [WEBサイトをリニューアルしました。](https://www.liberothera.com/news/webサイトをリニューアルしました。/) - [東京医科歯科大学と東京都が締結した「創薬・医療系オープンイノベーションに資する大学保有機器等の共用に 関する協定」のPR動画に、当社代表取締役の菅家徹が出演しました。](https://www.liberothera.com/news/0716-2020/) - [BioJapanの東京大学協創プラットフォーム開発（東大IPC）主催セミナーに登壇します](https://www.liberothera.com/news/1011-2021/) - [本店所在地を変更しました。](https://www.liberothera.com/news/0501-2022/) - [研究所を東京都文京区に移転しました。](https://www.liberothera.com/news/0601-2022/) - [リベロセラ株式会社とBiocytogenの戦略的共同研究成果（GPCR標的 CCR8）の公表について](https://www.liberothera.com/news/0721-2022/) - [Taiho Ventures, LLCから約3億円の資金調達を実施](https://www.liberothera.com/news/0805-2021/) - [追加出資ラウンドで総額5.4億円の資金調達を実施](https://www.liberothera.com/news/0514-2021/) - [リベロセラ株式会社とBiocytogenの戦略的共同研究契約の締結について](https://www.liberothera.com/news/0201-2021/) - [菅家徹が代表取締役に就任しました。](https://www.liberothera.com/news/0626-2020/) - [本店所在地を変更しました。](https://www.liberothera.com/news/0401-2019/) - [東京都中央区に研究所を開設しました。](https://www.liberothera.com/news/0204-2019/) - [横浜市鶴見区にオフィスを開設しました。](https://www.liberothera.com/news/1101-2018/) - [WEBサイトを公開しました。](https://www.liberothera.com/news/0831-2/) ## News - [LiberoThera Appoints Yoichi Okumura as CEO](https://www.liberothera.com/news-en/liberothera-appoints-yoichi-okumura-as-ceo/) - [LiberoThera Closes 720 Million JPY of Additional Funding to Accelerate the Discovery and Development of its Antibody-based Therapeutics](https://www.liberothera.com/news-en/liberothera-closes-720-million-jpy-of-additional-funding-to-accelerate-the-discovery-and-development-of-its-antibody-based-therapeutics/) - [Presentation of anti-CCR8 antibody data at the American Association for Cancer Research Annual Meeting 2024](https://www.liberothera.com/news-en/presentation-of-anti-ccr8-antibody-data-at-the-american-association-for-cancer-research-annual-meeting-2024/) - [Renewed our website.](https://www.liberothera.com/news-en/renewed-our-website/) - [LiberoThera and Biocytogen Achieve Milestone Progress in Co-Development of Fully Human GPCR Antibody Drugs](https://www.liberothera.com/news-en/0721-2022/) - [Announced relocation of research laboratory.](https://www.liberothera.com/news-en/0601-2022/) - [Registered Office Address has been changed.](https://www.liberothera.com/news-en/0501-2022/) - [LiberoThera Secures 300 Million JPY Financing Agreement with Taiho Ventures](https://www.liberothera.com/news-en/0805-2021/) - [LiberoThera Closes 535 Million JPY Financing to Develop GPCR-targeting Therapeutics](https://www.liberothera.com/news-en/0514-2021/) - [LiberoThera and Biocytogen Enter into Strategic Collaboration Agreement](https://www.liberothera.com/news-en/0201-2021/) - [Toru Kanke, Ph.D. has been appointed as CEO.](https://www.liberothera.com/news-en/0626-2020/) - [Registered Office Address has been changed as shown below.](https://www.liberothera.com/news-en/0401-2019/) - [LiberoThera opened Nihonbashi Laboratory in Chuo-ku, Tokyo.](https://www.liberothera.com/news-en/0204-2019/) - [LiberoThera opened Tsurumi Office in Tsurumi-ku, Yokohama.](https://www.liberothera.com/news-en/1101-2018/) - [This corporate website was opened to the public.](https://www.liberothera.com/news-en/this-corporate-website-was-opened-to-the-public/)